Amanda Bartelme is the director of Reimbursement, US Policy at GSK. In her role, she is the primary subject matter expert on public funding policies (Medicare and Medicaid) for GSK’s inline and pipeline products. Amanda also responsible for the coordination, completion and filing for all relevant coding applications with required organizations including CMS & AMA and leads policy analysis, policy development, and internal and external thought leadership on key issues surrounding therapy access including Medicaid, Medicare Part A & B and the 340B program.

Prior to joining GSK, Amanda spent 12 years at Avalere Health, a Washington-based healthcare advisory firm, serving as Vice President of their Reimbursement and Product Commercialization practice. At Avalere, she assisted clients across pharmaceutical, biotech, medical device, patient advocacy, and healthcare provider communities in ensuring patients have appropriate access to drugs, biologics, medical devices, procedures, and services. Amanda joined Baxalta (now Shire) in October 2015, focusing on US policy and later global policy for the company’s hemophilia, immunology, oncology, and neurology divisions. Amanda’s specific areas of expertise are Medicare payment policy, HCPCS coding, the 340B Drug Pricing Program, Medicare Part B drug policy, and federal drug price reporting programs (e.g., Average Sales Price, Average Manufacturers Price).

She is an established expert in diabetes, working extensively with JDRF (formerly the Juvenile Diabetes Research Foundation) to ensure people living with type 1 diabetes have access to the best available tools and treatment options. In addition, she served for seven years on the NCQA/AMA-PCPI Joint Diabetes Expert Panel, helping to review and develop diabetes-specific quality measures. In addition to diabetes, Amanda has deep expertise in hemophilia policy and served for four terms on board of the Hemophilia Association of the Capital Area.

Amanda holds a BS in sociology from Cornell University.

Jack is Director of Healthcare Policy, Medicaid and State Initiatives. In addition to all Medicaid issues, Jack covers federal and state issues related to Transparency, 340B, value-based arrangements, Children’s Health Insurance Program (CHIP), and any other issues that arise from state legislation and regulation.

Jack has more than 24 years of health policy and advocacy experience working on pharmaceutical, pharmacy, and insurance issues. Before moving to BIO, he led the State Policy function at Eisai for 9 years. Prior to Eisai he was a Director, State Policy at the Pharmaceutical Research and Manufacturers of America (PhRMA) where he testified on a variety of issues in more than 33 states. Before moving to PhRMA, he created the Government Relations Department at the Academy of Managed Care Pharmacy (AMCP). Prior to AMCP he worked on pharmaceutical and provider issues at federal lobbying firms in Washington, DC.

Jack has a BA from St. Anselm College and a Masters degree in Political Science with a concentration in Public Policy.

Chris Hatwig has served as president of Apexus, the nation's leader in the advancement of ambulatory pharmacy solutions and the support of compliant 340B programs, since 2004. Apexus is best known for its role as Health Resources and Services Administration’s contracted 340B Prime Vendor, serving all 340B stakeholders. Recently, Apexus has expanded its service offerings to include the Apexus Manufacturer Refund Service and Acentrus, the health system specialty pharmacy program. Throughout his career, Chris has been committed to developing and implementing solutions to improve efficient access to affordable medications between 340B stakeholders and the patients they support.

Before joining Apexus, Chris was the director of Ambulatory Pharmacy Services and Value Analysis Programs at Parkland Health & Hospital System in Dallas, where he practiced for 13 years, managing one of the nation’s largest and most progressive safety net ambulatory pharmacy programs. Mr. Hatwig received his bachelor’s degree in pharmacy from the University of Arkansas. He completed residencies in hospital pharmacy and hospital pharmacy administration at the University of Wisconsin, culminating in an MS in hospital pharmacy.

BILL SARRAILLE is a senior member of the Healthcare practice group and a nationally-recognized lawyer in healthcare law. Bill concentrates on a variety of healthcare matters, including Medicare and Medicaid reimbursement, coverage and coding, pharmaceutical price reporting, issues related to the marketing and promotion of pharmaceuticals and medical devices, internal investigations, clinical research issues, Stark and Anti-Kickback Law analyses, Medicare and Medicaid audits, healthcare acquisitions and due diligence, compliance program audits, managed care matters, healthcare contracts, administrative litigation, legislative matters, privacy and security, coverage for new devices and services, the Foreign Corrupt Practices Act, international compliance and healthcare contracting, the representation of witnesses and companies before Congressional Committees, and the defense of healthcare criminal and False Claims Act matters. Bill has defended clients in some of the largest healthcare fraud investigations brought by the U.S. Government.

Bill’s clients have included pharmaceutical companies, biotechnology companies, device and equipment manufacturers, diagnostics manufacturers, academic medical centers, hospitals, health systems, faculty practice plans, durable medical equipment suppliers, healthcare consulting firms, ambulatory surgical centers, physician practice management companies, managed service organizations, managed care organizations, large physician group practices, imaging centers, financial institutions, contract research organizations, and leading healthcare trade associations and professional societies.

Bill is consistently recognized as a leading healthcare lawyer in Chambers USA and LMG Life Sciences. He was named an LMG Life Sciences star in 2013, 2014 and 2015, and has been recognized every year since 2013 in Chambers USA as a leading lawyer both in D.C. and nationwide. Chambers notes that sources describe Bill as a “terrific regulatory healthcare lawyer” with a "wide range of experience” and noted he is “an excellent reimbursement lawyer.” The directory has also described him as “‘an intellectual heavyweight. He is hugely professional on every issue.’” It also listed Bill as “a very good communicator and a trusted adviser.” Recognized in the 2016 edition of Who’s Who Legal: Life Sciences, they noted “He superbly handles all the regulatory issues encountered by his clients.”

Washingtonian magazine includes Bill on its 2013 list of Washington’s Best Lawyers as one of the region’s “best legal minds” in the area of Healthcare Law. He was listed by Nightingale’s Healthcare News as one of ten “Outstanding Practice Lawyers for 2006.” He is the co-author of several books on healthcare. Bill served on the Regulatory Relief Committee for the American Hospital Association and served on the Compliance Advisory Committee for the Healthcare Financial Management Association as its Chairman. He served as a law clerk to the Honorable Harry L. Hupp in the U.S. District Court for the Central District of California in Los Angeles following his graduation from Harvard Law School in 1989.

David Twitchell, PharmD, MBA has nearly twenty years of experience as a business leader in the healthcare industry. He currently serves as Vice President and Chief Pharmacy Officer for Boston Medical Center Health System (BMCHS) which is home to the largest safety net hospital in New England and operates a MassHealth plan that has more than 400,000 covered lives. In this role, he oversees all pharmacy operations and clinical activity for the hospital, clinics, retail, specialty, mail order and health insurance departments.

At BMCHS, he has led the development of a new inpatient model for operations, including supply chain management and clinical focused quality improvement projects, resulting in millions of dollars of direct savings and measurable improvements in clinical care delivery.

During his tenure at BMCHS, Twitchell has led the development and launch of specialty pharmacy services which include a consulting and staffing arm, mail order services, and hospital-based pharmacies, all of which generate approximately $300M each year.

Prior to his current role at BMCHS, Twitchell founded and operationalized a private equity backed firm dedicated to helping heath systems develop specialty pharmacy services. He also served as a Critical Care Clinical Specialist at Swedish Medical Center in Englewood, CO and the Director of Pharmacy at North Suburban Medical Center in Thornton, CO.

Twitchell received his Bachelor of Science degree in pharmacy studies and his Doctorate in pharmacy from the University of Connecticut, College of Pharmacy. He also holds a Master’s in Business Administration from the University of Phoenix.

Aaron Vandervelde is a Managing Director in BRG’s Health Analytics practice and has over 15 years of experience providing strategy, health policy and litigation consulting services to clients in the healthcare industry. He specializes in financial and economic analysis and provides strategy, operational and litigation consulting services related to issues arising from contracts and transactions between healthcare entities and with the federal government. Specifically, he focuses on deriving strategic insight through the integration and analysis of large, complex data sets including claims data, risk adjustment data, internal and external sales data and publicly available health data.

Charles is the Director of Pfizer’s Fraud Investigations Group and has responsibility for 340B Program Integrity. He leads a multi-disciplinary team that addresses all 340B remediation efforts. He developed Pfizer’s current 340B remediation program which has been successful in creating value for both the Company and the 340B covered entities. Charles is an APEXUS 340B University facility member and a frequent speaker on 340B remediation from a manufacturer’s perspective.